Ashford 6: - Week 5 – Assignment Cardiovascular Disease Case Study Cardiovascular disease (CVD) is the number one killer of both men and women in the United States (American Heart Association, 2013). Many risk factors are associated with CVD. A risk factor is a variable which can increase a person’s risk of developing a disease such as family history, obesity, high blood pressure, or high cholesterol. Chronic diseases, such as heart disease, can have a direct impact on a person’s wellness. Making healthy lifestyle changes can decrease a person’s risk of heart disease and other chronic diseases. Examine the relationship between cardiovascular health status and wellness by completing the Assessment Activity 2-2: A Case Study of Bill M. on page 73 in your course textbook. For this assignment, the following questions from the end of the case study should be rewritten and then answered in a Word document: •What are Bill's risk factors for coronary heart disease? •Which factors can he control? •What suggestions can you give him regarding his current diet? •What effects may a change in diet have on his coronary risk profile? •What suggestions can you make regarding Bill's need for exercise, and how might a change in his activity level affect his coronary risk profile? •What are the risks associated with obesity? This assignment should be a minimum of two pages (excluding the title page and reference page). Answers must be Read “Transferring Innovation across National Borders” and prepare answers to the following questions: 1. What triggered the new product strategy at Minnesota Biolabs (MB)? 2. What prediction would you make for the success of getting the country general managers in Europe and Japan to adopt the new product? Explain your prediction. 3. What changes might MB make in its design in order to better promote the transfer of new prod- ucts across national borders? TRANSFERRING INNOVATION ACROSS NATIONAL BOUNDARIES Imagine entering a hospital for treatment of a medical condition only to come down with a far more serious, perhaps even life-threatening disease caused by that very treatment.30 That, unfortunately, is an increasingly common experience in hospitals located in the United States and elsewhere. The culprit is often an infection transferred to the patient through a tainted “injectable”: that is, a needle, an IV drip, and so forth. This is known as a sepsis infection: an overwhelming infection of the blood stream resulting from toxin-producing bacteria (endotoxins). National health regulatory agencies seek to limit such negative outcomes by requiring that products intended for injection be tested. Minnesota Biolabs Traditionally, tests for sepsis infection were performed on live animals—rabbits, for the most part—lead to the animal’s death. Minnesota Biolabs (MB) was one of the companies that supplied rabbits to the producers of injectable devices. Hea ...

1. Ashford 6: - Week 5 – Assignment
Cardiovascular Disease Case Study
Cardiovascular disease (CVD) is the number one killer of both
men and women in the United States (American Heart
Association, 2013). Many risk factors are associated with CVD.
A risk factor is a variable which can increase a person’s risk of
developing a disease such as family history, obesity, high blood
pressure, or high cholesterol. Chronic diseases, such as heart
disease, can have a direct impact on a person’s wellness.
Making healthy lifestyle changes can decrease a person’s risk of
heart disease and other chronic diseases.
Examine the relationship between cardiovascular health status
and wellness by completing the Assessment Activity 2-2: A
Case Study of Bill M. on page 73 in your course textbook. For
this assignment, the following questions from the end of the
case study should be rewritten and then answered in a Word
document:
•What are Bill's risk factors for coronary heart disease?
•Which factors can he control?
•What suggestions can you give him regarding his current diet?
•What effects may a change in diet have on his coronary risk
profile?
•What suggestions can you make regarding Bill's need for
exercise, and how might a change in his activity level affect his
coronary risk profile?
•What are the risks associated with obesity?
This assignment should be a minimum of two pages (excluding
the title page and reference page). Answers must be
Read “Transferring Innovation across National Borders”
and prepare answers to the following questions:

2. 1. What triggered the new product strategy at
Minnesota Biolabs (MB)?
2. What prediction would you make for the success
of getting the country general managers in Europe and Japan to
adopt the new product?
Explain your prediction.
3. What changes might MB make in its design in
order to better promote the transfer of new prod-
ucts across national borders?
TRANSFERRING INNOVATION ACROSS NATIONAL
BOUNDARIES
Imagine entering a hospital for treatment of a medical
condition only to come
down with a far more serious, perhaps even life-threatening
disease caused by
that very treatment.30 That, unfortunately, is an increasingly
common experience
in hospitals located in the United States and elsewhere. The
culprit is often an
infection transferred to the patient through a tainted
“injectable”: that is, a needle,
an IV drip, and so forth. This is known as a sepsis infection: an

3. overwhelming
infection of the blood stream resulting from toxin-producing
bacteria (endotoxins).
National health regulatory agencies seek to limit such negative
outcomes by
requiring that products intended for injection be tested.
Minnesota Biolabs
Traditionally, tests for sepsis infection were performed on live
animals—rabbits,
for the most part—lead to the animal’s death. Minnesota
Biolabs (MB) was one
of the companies that supplied rabbits to the producers of
injectable devices.
Headquartered in suburban Minneapolis, MB served
customers—mainly phar-
maceuticals but also university and private laboratories—in
over 20 countries.
Europe was divided into three MB national units, MB-France,
MB-Germany, and
MB-United Kingdom. A fourth country unit, MB-Japan, served
Asian markets.
Each of those four units—France, Germany, the United
Kingdom, and

4. Japan—was managed by a country general manager. That
general manager was
typically left alone to operate his or her unit autonomously.
Corporate headquar-
ters set annual growth goals for the units and measured their
profit and loss. As
long as the units performed according to those goals, the
managers were paid a
bonus and mostly left alone. Strategies, product decisions, and
acquisitions were
determined by corporate executives in the States and
communicated to these country managers.
MB’s CEO frequently said that he liked this approach to
management
because it delineated clear lines of authority and responsibility.
Country manag-
ers also preferred this autonomy. They were allowed, they
believed, to decide on
local strategies that best served their customers while
maintaining good relation-
ships with the national regulatory agencies to which they
needed to respond.
MB’s exceptional history of sustained, profitable growth
reinforced the belief of

5. managers that this was a well-designed organization. The
Search for an Alternative Test
In the early years of the 21st century, MB began to look for an
alternative method
of testing for sepsis infection in injectable products. As animal
rights became
increasingly important,MB sought a methodology that would
leave the animals
alive. Because most of MB’s growth over its history had come
from acquiring
other businesses and integrating their products into the
company’s offering, that
is what MB executives sought to do now.
An opportunity arose when a small, Rhode Island-based
company received
government approval for a test known as Sepsis Detection Test
(SDT). Instead of
conducting tests in live rabbits, SDT used blood extracted from
horseshoe crabs
for the tests. After extraction, the crabs were returned to the
ocean where they
were able to regenerate lost blood. MB purchased the company,
and horseshoe
crab-based testing quickly became the standard for the United

6. States. In addition
to leaving test animals alive, SDT was both less costly and more
profitable for
MB than the previous rabbit tests.
After several years of rapid growth in its home market, MB
executives
urged country general managers in Europe and Japan to move
from rabbit-based
tests to SDT. At the annual strategy meeting in Minneapolis,
corporate execu-
tives presented the business case for SDT and urged the country
general manag-
ers of MB-France, MB-German, MB-United Kingdom, and MB-
Japan to switch
over their product line. The country general managers agreed to
move forward
as quickly as possible.
Pg 89